Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

Blood (2022) 140 (Supplement 1): 6356–6357.

https://doi.org/10.1182/blood-2022-165985

Published: 2022

Journal Articles

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Blood (2022) 140 (Supplement 1): 1009–1010.

https://doi.org/10.1182/blood-2022-162930

Published: 2022

Journal Articles

Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Bela Patel Wrench, Amy A. Kirkwood, Krisztina Zuborne Alapi, Laura Clifton-Hadley, SooWah Lee, David I. Marks, Anthony V. Moorman, Nicholas J. Morley, Pip Patrick, Zaynab Rana, Clare J. Rowntree, John A. Snowden, Adele K. Fielding

Blood (2022) 140 (Supplement 1): 6125–6126.

https://doi.org/10.1182/blood-2022-159958

Published: 2022

Journal Articles

Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination

Jesús Gutiérrez-Abril, Daniel Leongamornlert, Neerav N Shukla, Maria Luisa Sulis, Yangyu Zhou, Max F. Levine, Emilio Barretta, SooWah Lee, Juan E. Arango-Ossa, Gunes Gundem, Juan S. Medina-Martínez, Bela Patel Wrench, Anthony V. Moorman, Adele K. Fielding, Andrew L. Kung, Elli Papaemmanuil

Blood (2022) 140 (Supplement 1): 1197–1199.

https://doi.org/10.1182/blood-2022-160322

Published: 2022

Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 739.

https://doi.org/10.1182/blood-2019-123374

Published: 2019

NARROW

Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Email alerts

ASH Publications

American Society of Hematology

Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only